
Releases
Investors Target ARS Pharmaceuticals in Federal Securities Lawsuit
A federal class action lawsuit now challenges ARS Pharmaceuticals, accusing the company and its executives of misleading investors regarding the insurance coverage timeline for its product, neffy. The litigation focuses on statements made between March 9 and June 24, 2026, a period marked by alleged material omissions.


























